ArticleGut2003
Local delivery of adenoviral vectors encoding murine interleukin 10 induces colonic interleukin 10 production and is therapeutic for murine colitis.
Article in Gut, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Oral nucleic acid therapy using multicompartmental delivery systems.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2018Review
- Targeting the gastrointestinal tract with viral vectors: state of the art and possible applications in research and therapy.Histochemistry and cell biology · 2016Review
- Treatment of dextran sodium sulfate-induced experimental colitis by adoptive transfer of peritoneal cells.Scientific reports · 2015Article
- Serine protease inhibitors protect better than IL-10 and TGF-β anti-inflammatory cytokines against mouse colitis when delivered by recombinant lactococci.Microbial cell factories · 2015Article
- Article
- Effect of adenovirus-mediated PTEN gene on ulcerative colitis-associated colorectal cancer.International journal of colorectal disease · 2013Article
- Interleukin-10 and interleukin-10-receptor defects in inflammatory bowel disease.Current allergy and asthma reports · 2012Review
- Future therapeutic approaches for inflammatory bowel diseases.Gastroenterology · 2011Review
- Role of the endothelium in inflammatory bowel diseases.World journal of gastroenterology · 2011Review
- Enhanced transduction of colonic cell lines in vitro and the inflamed colon in mice by viral vectors, derived from adeno-associated virus serotype 2, using virus-microbead conjugates bearing lectin.BMC biotechnology · 2007Article
- IL-10 gene therapy is therapeutic for dextran sodium sulfate-induced murine colitis.Digestive diseases and sciences · 2004Article
Corrections and comments
- Retraction · 2004-04-13Duplication of Content through Error by Journal/Publisher ·
- RetractedRetraction.2004
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionInterleukin 10 knockout (IL-10-/-) mice spontaneously develop a Th1 T cell mediated colitis with many similarities to Crohn's disease. Daily injections of IL-10 are unable to induce remission in mice with established disease. In contrast, we have shown previously that intravenous administration of adenoviral vectors encoding IL-10 (AdvmuIL-10) induces hepatic IL-10 release and leads to long term disease suppression with profound systemic immunoregulatory changes.
aimsTo determine whether rectal delivery of AdvmuIL-10 induces localised colonic IL-10 expression without systemic immune suppression, and assess its therapeutic efficacy in IL-10-/- mice with established colitis.
resultsA single rectal infusion of 5 x 10(8) PFU AdvmuIL-10 to 10 week IL- 10-/- mice resulted in a median level of 27.3 pg/mg IL-10 in colonic homogenates harvested one week later. IL-10-/- mice with established colitis treated with an enema of 5 x 10(8) PFU AdvmuIL-10 entered clinical and histological remission whereas empty cassette adenovirus (Adv0) or phosphate buffered saline (PBS) treated mice developed progressive disease. After four weeks, the histological score of AdvmuIL-10 treated mice (4.4 (1.5)) was significantly lower than that of Adv0 (11.1 (1.1); p<0.001) and PBS (10.9 (1.0); p<0.01) treated controls. In addition, the stool concentration of IL-1beta over the four week experiment was significantly higher in mice treated with saline or Adv0 than in those treated with AdvmuIL-10 (p<0.01).
conclusionLocal AdvmuIL-10 therapy reverses colitis in IL-10-/- mice without the systemic effects seen after intravenous administration. Gene therapy strategies using adenoviral vectors encoding immunoregulatory cytokines may prove to be a potent approach to the treatment of chronic inflammatory diseases such as Crohn's disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.